214 related articles for article (PubMed ID: 25216334)
1. In silico discovery of potential VEGFR-2 inhibitors from natural derivatives for anti-angiogenesis therapy.
Li J; Zhou N; Luo K; Zhang W; Li X; Wu C; Bao J
Int J Mol Sci; 2014 Sep; 15(9):15994-6011. PubMed ID: 25216334
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, and Biological Evaluation of Axitinib Derivatives.
Wei N; Liang J; Peng S; Sun Q; Dai Q; Dong M
Molecules; 2018 Mar; 23(4):. PubMed ID: 29570686
[TBL] [Abstract][Full Text] [Related]
3. Molecular Interaction and Computational Analytical Studies of Pinocembrin for its Antiangiogenic Potential Targeting VEGFR-2: A Persuader of Metastasis.
Sharma N; Sharma M; Shakeel E; Jamal QMS; Kamal MA; Sayeed U; Khan MKA; Siddiqui MH; Arif JM; Akhtar S
Med Chem; 2018; 14(6):626-640. PubMed ID: 29663896
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, biological evaluation and dynamics simulation of indazole derivatives with antiangiogenic and antiproliferative anticancer activity.
Elsayed NMY; Serya RAT; Tolba MF; Ahmed M; Barakat K; Abou El Ella DA; Abouzid KAM
Bioorg Chem; 2019 Feb; 82():340-359. PubMed ID: 30428414
[TBL] [Abstract][Full Text] [Related]
5. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.
Pemovska T; Johnson E; Kontro M; Repasky GA; Chen J; Wells P; Cronin CN; McTigue M; Kallioniemi O; Porkka K; Murray BW; Wennerberg K
Nature; 2015 Mar; 519(7541):102-5. PubMed ID: 25686603
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
7. Development of a highly-potent anti-angiogenic VEGF8-109 heterodimer by directed blocking of its VEGFR-2 binding site.
Ghavamipour F; Shahangian SS; Sajedi RH; Arab SS; Mansouri K; Aghamaali MR
FEBS J; 2014 Oct; 281(19):4479-94. PubMed ID: 25132001
[TBL] [Abstract][Full Text] [Related]
8. Two anti-angiogenic TKI-PET tracers, [(11)C]axitinib and [(11)C]nintedanib: Radiosynthesis, in vivo metabolism and initial biodistribution studies in rodents.
Slobbe P; Poot AJ; Haumann R; Schuit RC; Windhorst AD; van Dongen GA
Nucl Med Biol; 2016 Oct; 43(10):612-24. PubMed ID: 27497236
[TBL] [Abstract][Full Text] [Related]
9. Virtual Screening, Docking, and Designing of New VEGF Inhibitors as Anti-cancer Agents.
Patel S; Singh VR; Suman AK; Jain S; Sen AK
Curr Drug Discov Technol; 2024; 21(1):e101023222024. PubMed ID: 38629172
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 6-Arylurea-2-arylbenzoxazole and 6-Arylurea-2-arylbenzimidazole Derivatives as Angiogenesis Inhibitors: Design, Synthesis and in vitro Biological Evaluation.
Zi M; Liu F; Wu D; Li K; Zhang D; Zhu C; Zhang Z; Li L; Zhang C; Xie M; Lin J; Zhang J; Jin Y
ChemMedChem; 2019 Jul; 14(13):1291-1302. PubMed ID: 31131561
[TBL] [Abstract][Full Text] [Related]
11. Structure-based identification of potent VEGFR-2 inhibitors from in vivo metabolites of a herbal ingredient.
Dash R; Junaid M; Mitra S; Arifuzzaman M; Hosen SMZ
J Mol Model; 2019 Mar; 25(4):98. PubMed ID: 30904971
[TBL] [Abstract][Full Text] [Related]
12. Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling.
Zhou X; Yue GG; Liu M; Zuo Z; Lee JK; Li M; Tsui SK; Fung KP; Sun H; Pu J; Lau CB
Oncotarget; 2016 Dec; 7(50):82820-82835. PubMed ID: 27756875
[TBL] [Abstract][Full Text] [Related]
13. Short-term treatment with VEGF receptor inhibitors induces retinopathy of prematurity-like abnormal vascular growth in neonatal rats.
Nakano A; Nakahara T; Mori A; Ushikubo H; Sakamoto K; Ishii K
Exp Eye Res; 2016 Feb; 143():120-31. PubMed ID: 26500193
[TBL] [Abstract][Full Text] [Related]
14. Quantifying the relationship between inhibition of VEGF receptor 2, drug-induced blood pressure elevation and hypertension.
Collins T; Gray K; Bista M; Skinner M; Hardy C; Wang H; Mettetal JT; Harmer AR
Br J Pharmacol; 2018 Feb; 175(4):618-630. PubMed ID: 29161763
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis and Evaluation of 5-pyridin-4-yl-2-thioxo-[1,3,4]oxadiazol-3-yl Derivatives as Anti-angiogenic Agents Targeting VEGFR-2.
Bhanushali U; Kalekar-Joshi S; Kulkarni-Munshi R; Yellanki S; Medishetty R; Kulkarni P; Chelakara RS
Anticancer Agents Med Chem; 2017; 17(1):67-74. PubMed ID: 27141880
[TBL] [Abstract][Full Text] [Related]
16. Pharmacophore-Based Virtual Screening and In-Silico Explorations of Biomolecules (Curcumin Derivatives) of
Ejaz SA; Aziz M; Fawzy Ramadan M; Fayyaz A; Bilal MS
Molecules; 2023 May; 28(10):. PubMed ID: 37241785
[TBL] [Abstract][Full Text] [Related]
17. Exploration of N-(2-aminoethyl)piperidine-4-carboxamide as a potential scaffold for development of VEGFR-2, ERK-2 and Abl-1 multikinase inhibitor.
Jin F; Gao D; Wu Q; Liu F; Chen Y; Tan C; Jiang Y
Bioorg Med Chem; 2013 Sep; 21(18):5694-706. PubMed ID: 23932071
[TBL] [Abstract][Full Text] [Related]
18. Anti-Angiogenic Therapy: Strategies to Develop Potent VEGFR-2 Tyrosine Kinase Inhibitors and Future Prospect.
Shi L; Zhou J; Wu J; Shen Y; Li X
Curr Med Chem; 2016; 23(10):1000-40. PubMed ID: 26860998
[TBL] [Abstract][Full Text] [Related]
19. In silico insights into the identification of potential novel angiogenic inhibitors against human VEGFR-2: a new SAR-based hierarchical clustering approach.
Konidala KK; Bommu UD; Pabbaraju N
J Recept Signal Transduct Res; 2018 Aug; 38(4):372-383. PubMed ID: 30396316
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Small Molecules that Target Vascular Endothelial Growth Factor Receptor-2 Signalling Pathway Employing Molecular Modelling Studies.
Rampogu S; Baek A; Park C; Parate S; Parameswaran S; Park Y; Shaik B; Kim JH; Park SJ; Lee KW
Cells; 2019 Mar; 8(3):. PubMed ID: 30901950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]